Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor

[Image: see text] Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Arasappan, Ashok, Bennett, Frank, Bogen, Stephane L., Venkatraman, Srikanth, Blackman, Melissa, Chen, Kevin X., Hendrata, Siska, Huang, Yuhua, Huelgas, Regina M., Nair, Latha, Padilla, Angela I., Pan, Weidong, Pike, Russell, Pinto, Patrick, Ruan, Sumei, Sannigrahi, Mousumi, Velazquez, Francisco, Vibulbhan, Bancha, Wu, Wanli, Yang, Weiying, Saksena, Anil K., Girijavallabhan, Viyyoor, Shih, Neng-Yang, Kong, Jianshe, Meng, Tao, Jin, Yan, Wong, Jesse, McNamara, Paul, Prongay, Andrew, Madison, Vincent, Piwinski, John J., Cheng, Kuo-Chi, Morrison, Richard, Malcolm, Bruce, Tong, Xiao, Ralston, Robert, Njoroge, F. George
Médium: Artigo
Jazyk:Inglês
Vydáno: American Chemical Society 2010
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007962/
https://ncbi.nlm.nih.gov/pubmed/24900178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml9000276
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky